A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2002
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156099 1-acyl-piperidine substance p antagonist; used to treat central nervous system disorders and respiratory diseases
10/24/2002	US20020156096 Two 5- amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group; cholinesterase inhibitors
10/24/2002	US20020156095 Treatment of depression, anxiety, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, respiratory diseases, inflammatory diseases, neuropathy, immune disorders, etc.
10/24/2002	US20020156094 Sulfonamide interleukin-1beta converting enzyme inhibitors
10/24/2002	US20020156093 (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-y l) acetonitrile or its salt to treat psychological disorders
10/24/2002	US20020156091 Dosing interval of the nimesulide overlaps with that of the oxycodone to reduce the amount of oxycodone needed to provide an effect
10/24/2002	US20020156090 Estrogen agonist/antagonist to prevente myocardial infarction or stroke, maintaining or improving vascular reactivity, treat renal failure, peripheral arterial occlusive disease, coronary artery disease, or raynaud's phenomenon
10/24/2002	US20020156089 Use of CRF antagonists and related compositions
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156078 Use of molindone to treat oppositional defiant disorder and conduct disorder
10/24/2002	US20020156070 Felbamate derived compounds
10/24/2002	US20020156069 Benzo thiadiazine matrix metalloproteinase inhibitors
10/24/2002	US20020156067 New drug combinations
10/24/2002	US20020156061 Administering to a mammal a matrix metalloproteinase inhibiting amount of derivatives of isophthalic acid, isophthalic acid ester or isothalamide compounds to treat cancer, rheumatic arthritis atherosclerosis and osteoporosis
10/24/2002	US20020156053 Treating gastro-oesophageal reflux disease
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156040 Antisense oligonucleotides that bind to the enzyme's start codon; inhibiting enzymes such as superoxide dismutase
10/24/2002	US20020156036 Expression vector encoding a fusion protein with segments of a region which binds to an epitope or fragment and fragment or whole proteins that can cross the blood brain barrier
10/24/2002	US20020156030 Heterocyclic aromatic compounds and uses thereof
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155577 Compound for use in the treatment of parkinson's disease
10/24/2002	US20020155552 "prionins", highly specific markers for noninvasive pre-symptomatic detection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
10/24/2002	US20020155539 Calcium channel polynucleotides, polypeptides, and antibodies
10/24/2002	US20020155534 SBHWSB2: a new member of the WD40 SOCS box family
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155426 Prevention and treatment of amyloid-associated disorders
10/24/2002	US20020155170 Detoxification of heavy metals; adjustment concentration of metallothionein
10/24/2002	US20020155158 For controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides
10/24/2002	US20020155144 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155103 Activated charcoal based composition and method for reducing hangover symptomps associated with the consumption of alcohol containing beverages
10/24/2002	US20020155098 Methods for treating the inflammatory component of a brain disorder
10/24/2002	US20020155067 For drug delivery
10/24/2002	EP1212298A4 Isolation of natural l-beta-3-indolylalanine and enrichment of natural aliphatic amino acid mixtures with natural l-beta-3-indolylalanine
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	DE10117281A1 Peptid zur Diagnose und Therapie der Alzheimer-Demenz Peptide for diagnosis and therapy of Alzheimer's disease
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2445990A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2444530A1 Polypeptides, derivatives and uses thereof
10/24/2002	CA2444465A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	CA2444267A1 Prodrugs of cox-2 inhibitors
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444220A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2444148A1 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
10/24/2002	CA2443906A1 Novel oral general anesthetics and metabolitically resistant anticonvulsants
10/24/2002	CA2443900A1 Methods of treating prion disease in mammals comprising administering a chaotropic agent such as guanidine, urea or potassium iodide
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443811A1 Type b botulism toxin inhibitors
10/24/2002	CA2443805A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	CA2443777A1 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443577A1 Nicotinic acetylcholine receptor ligands
10/24/2002	CA2443568A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443567A1 Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereofas tocolytic oxytocin receptor antagonists
10/24/2002	CA2443490A1 Tricyclic diazepines as tocolytic oxytocin receptor antagonists
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2442943A1 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
10/24/2002	CA2442729A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	CA2440842A1 Novel 1h-indazole compounds
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251137A2 Use of insulin-like growth factor agonist peptides
10/23/2002	EP1251132A1 Synthesis of (3aS)-5,5-dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine
10/23/2002	EP1251131A2 Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1251120A1 Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl
10/23/2002	EP1250931A1 Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
10/23/2002	EP1250923A2 Use of selective PDE10 inhibitors for the treatment of central nervous system disorders
10/23/2002	EP1250600A2 Diagnosis of tauopathies determining tau/phospho-tau ratio
10/23/2002	EP1250425A2 Secreted human proteins, polynucleotides encoding them and methods of using the same
10/23/2002	EP1250358A1 Therapeutic peptides
10/23/2002	EP1250354A1 Peptide fragments of colostrinin and their use
10/23/2002	EP1250338A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors
10/23/2002	EP1250336A1 Piperidine derivatives and their use as serotonin receptor antagonists
10/23/2002	EP1250328A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250323A2 Compounds having hypolipidemic and hypocholesterolemic activities, process for their preparation and pharmaceutical compositions containing them
10/23/2002	EP1250313A1 Monohydrate of cis-lithium-cyano-4- 3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate
10/23/2002	EP1250157A1 Antisense modulation of inducible nitric oxide synthase expression
10/23/2002	EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250136A1 Methods for the treatment of substance abuse
10/23/2002	EP1250132A1 Ibuprofen containing active agent preparation
10/23/2002	EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002	EP1091959B1 Novel pyrrolo-(3,4-b)quinoline derivatives, method for the production and use thereof as a medicament
10/23/2002	EP1086095B1 Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
10/23/2002	EP1073664B1 (alpha-aminophosphino) peptidesderivative and compositions containing same
10/23/2002	EP1066297B1 Phosphinic acid derivatives
10/23/2002	EP1061943B1 Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
10/23/2002	EP1000067B1 Thiazolobenzoheterocycles, preparation and medicines containing same
10/23/2002	EP1000063B1 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY

1 ... 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 ... 1833